📈 Stocks / Finance

Invivyd's Stock Surges on Strong Antibody Data, Revenue Growth

Benzinga

Invivyd shares jumped 72.8% after VYD2311 showed a 17-fold potency gain over pemivibart and sustained high serum levels. Q4 Pemgarda revenue rose 48% QoQ to $13.8M, signaling strong demand. With $69.3M in cash reserves and promising PK data suggesting extended efficacy, investors are betting on long-term commercial viability.

Tariffs Rattle Markets as China Retaliates

CNBC

Stock futures fell after China imposed tariffs of up to 15% on U.S. coal, LNG, crude oil, and farm equipment, retaliating against U.S. levies. Dow futures dropped 0.21%, S&P 500 lost 0.24%, and Nasdaq declined 0.2%. Despite volatility, analysts see buying opportunities, with markets eyeing key earnings and jobs data this week.

CFPB Overhaul: Bessent Halts Regulations Amid Leadership Shift

Yahoo Finance

Trump replaced CFPB director Rohit Chopra with Treasury Secretary Scott Bessent, who immediately froze the agency’s operations. Bessent suspended rulemaking, delaying policies like the $5 overdraft fee cap and medical debt credit reporting changes. An insider suggests the move aims to dismantle the agency.

🪙 Crypto

Ethereum Soars 25% Amid Market Volatility and Trump Endorsement

Fortune

Ethereum surged over 25% to $2,900 within 24 hours, reversing recent losses. The rally coincided with Eric Trump’s cryptic endorsement and speculation over Ethereum’s role in U.S. crypto strategy. Meanwhile, the Trump-backed DeFi project World Liberty Financial has reportedly been accumulating ETH, though its holdings remain unverified.

🌎 Global Economy

EUR/USD Weakens as US Tariffs Hit China

FXStreet

EUR/USD fell below 1.0300 after the US imposed a 10% tariff on China, strengthening the dollar. Trump hinted at imminent trade talks but warned of harsher tariffs if no deal is reached. The Euro remains pressured by dovish ECB policy, despite inflation rising to 2.5% YoY in January, driven by energy costs.